DESC:FIELD OF THE INVENTION
The present invention relates to a formulation and a method for a capsule and more particularly, the present invention relates to the formulation and method for a capsule to enhance the natural population of a stem cell in a body and to enhance regeneration and rejuvenation in a tissue.
BACKGROUND OF THE INVENTION
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more the stem cells. The Stem cells are found in multicellular organisms. In mammals, there are two broad types of the stem cells: an embryonic stem cells, which are isolated from the inner cell mass of a blastocysts, and an adult stem cells, which are found in various tissues. In adult organisms, the stem cells and a progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, the stem cells can differentiate into all the specialized cells—an ectoderm, an endoderm and a mesoderm but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues. The Stem cells have enormous potential in health and medical research. The Stem cell research can potentially help treat a range of medical problems.
US 20090110674A1 discloses a health supplement consisting of numerous ingredients from several general groups, including: anti-aging, anti-oxidant, vitamins, minerals, and the elemental substances including metals. The supplement is specifically formulated for maximizing synergistic interaction of the ingredients while eliminating harmful interaction among the ingredients.
US 5904924A discloses new nutritional powder composition of the invention is a blend of natural food and herbal products which is compounded in dry form into a green nutritional powder mixture which is readily soluble in a fluid for ingestion by humans.
2
US20110223191A1 discloses a comestible composition with anti-cancer property comprises alcohol soluble extracts from plant parts of piper species, palm species, tropical seaweeds, and/or solanum species.
US20050084547A1 discloses pharmaceutical compositions are made from extracts obtained from ethnobotanical plants for inducing apoptosis in selected cells. Therapeutically effective amounts of the composition are administered to a mammal.
The present invention is an advancement of already present invention in this field. The drawbacks of already existing inventions are that all the already existing inventions are less efficient and effective. In the already existing invention there is no such invention which is capable of producing such good results without any side effects. None of the existing invention uses the composition and the method that is disclosed in the present invention. The present invention effectively overcomes the deficiencies in the prior art. Hence there is a need for the present invention.
OBJECTIVE OF THE INVENTION
The main objective of the present invention is to enhance the natural population of the stem cell in the body.
The principal objective of the present invention is to enhance regeneration in the tissue.
Yet another objective of the present invention is to enhance rejuvenation in the tissues.
Further objectives, advantages and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example and appropriate reference to accompanying drawings.
3
SUMMARY OF THE PRESENT INVENTION
The present invention relates to regeneration and rejuvenation of the tissues and more particularly to the use of a capsule to enhance regeneration and rejuvenation in the tissues. Also, the invention deals with the treatment of a degenerative disorder, a metabolic disorder and a tissue repair with help of the capsule. The capsule contains various combinations of a formulation of various herbal plants. The total concentration of ingredients used in the formulation ranges between 300mg-500mg. The present invention relates to regeneration and rejuvenation of the tissues. The present invention use of the capsule to treat various types of disease present in human body. The capsule formulation increases the hematopoietic stem cell counts, the endothelial progenitor counts and the adult regenerative pluripotent stem cell counts. The capsule helps in production of and releases the stem cells in the body and blood. The capsule contains a solanum trilobatum, a mimosa pudica, a tribulus terrestris and a wheat grass. The concentration of the solanum trilobatum used in the formulation ranges between 50mg-250mg. The concentration of the mimosa pudica used in the formulation ranges between 50mg-250mg. The concentration of the wheat grass used in the formulation ranges between 50mg-250mg. The concentration of the tribulus terrestris used in the formulation ranges between 50mg-250mg. The capsule helps in production of and releases the stem cells in body and blood.
One advantage of the present invention is that the present invention is effective against ageing.
Another advantage of the present invention is to help to cure age related debilities.
Yet another advantage of the present invention is that the present invention is used to treat chronic diabetes.
Yet another advantage of the present invention that the present invention is very effective in wound healing.
Yet another advantage of the present invention that the present invention is very effective in treating anemia.
4
Yet another advantage of the present invention is that the present invention is very effective in treating diabetes.
Yet another advantage of the present invention is that the present invention is very effective against high bold pressure.
Yet another advantage of the present invention is that the present invention is used in the treatment of degenerative arthritis of the knee.
Yet another advantage of the present invention is that the present invention is used for treatment of neurodegenerative disorders.
Yet another advantage of the present invention is that the present invention is used in the treatment of fatigue
Yet another advantage of the present invention that the present invention is very effective in heart related diseases.
Yet another advantage of the present invention is that the present invention is very useful in the stem cell transplantation especially in cases of a cerebral palsy and an autism.
Yet another advantage of the present invention that the present invention is stem cell enhancer.
Yet another advantage of the present invention that the present invention is used in the treatment of pernicious and other anemia.
Yet another advantage of the present invention that the present invention is improves microcirculation.
Yet another advantage of the present invention that the present invention is improves muscle function.
5
Yet another advantage of the present invention that the present invention is effective against peripheral nerve problems.
Yet another advantage of the present invention that the present invention provides geriatric and old age support.
Yet another advantage of the present invention is that the present invention increases a hematopoietic stem cell counts, an endothelial progenitor counts and an adult regenerative pluripotent stem cell counts.
Further objectives, advantages and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example and appropriate reference to the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention can be understood in more detail by reading the subsequent detailed description in conjunction with the examples and references made to the accompanying drawings, wherein:
Fig. 1 illustrates a tabular representation of example 1 in accordance with the present invention.
Fig. 2 illustrates a graphical representation of example 1 in accordance with the present invention.
Fig. 3 illustrates a tabular representation of example 2 in accordance with the present invention.
Fig. 4 illustrates a graphical representation of example 2 in accordance with the present invention.
Fig. 5 illustrates a tabular representation of example 3 in accordance with the present invention.
6
Fig. 6 illustrates a graphical representation of example 3 in accordance with the present invention.
Fig. 7 illustrates a tabular representation of example 4 in accordance with the present invention.
Fig. 8 illustrates a graphical representation of example 4 in accordance with the present invention.
DETAILED DESCRIPTION OF THE INVENTION
While this invention is susceptible of embodiment in many different forms, there is shown in the drawings and will herein be described in detail specific embodiments, with the understanding that the present disclosure of such embodiments is to be considered as an example of the principles and not intended to limit the invention to the specific embodiments shown and described. In the description below, like reference numerals are used to describe the same, similar or corresponding parts in the several views of the drawings. This detailed description defines the meaning of the terms used herein and specifically describes embodiments in order for those skilled in the art to practice the invention.
DEFINITION
The terms “about” and “essentially” mean ±10 percent.
The terms “a” or “an”, as used herein, are defined as one or as more than one. The term “plurality”, as used herein, is defined as two or as more than two. The term “another”, as used herein, is defined as at least a second or more. The terms “including” and/or “having”, as used herein, are defined as comprising (i.e., open language). The term “coupled”, as used herein, is defined as connected, although not necessarily directly, and not necessarily mechanically.
The term “comprising” is not intended to limit inventions to only claiming the present invention with such comprising language. Any invention using the term comprising could be separated into
7
one or more claims using “consisting” or “consisting of” claim language and is so intended. The term “comprising” can be used interchangeably with the terms “having” or “containing”.
Reference throughout this document to “one embodiment”, “certain embodiments”,” an embodiment”, “another embodiment”, and “yet another embodiment” or similar terms means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of such phrases or in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments without limitation.
The term “or” as used herein is to be interpreted as an inclusive or meaning any one or any combination. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.
Term “means” preceding a present participle of an operation indicates a desired function for which there is one or more embodiments, i.e., one or more methods, devices, or apparatuses for achieving the desired function and that one skilled in the art could select from these or their equivalent in view of the disclosure herein and use of the term “means” is not intended to be limiting.
As used herein, the term "regeneration" generally refers to, but not limited to, the process of renewal, restoration, and growth that makes a genome, a cell, an organisms, and an ecosystem resilient to natural fluctuations or events that cause disturbance or damage.
As used herein, the term “rejuvenation" generally refers to, but not limited to, a medical discipline focused on the practical reversal of the aging process.
As used herein, the term “tissue” generally refers to, but not limited to, an ensemble of similar cells from the same origin that together carry out a specific function. The tissues are selected
8
from, but not limited to, a connective tissue, a muscle tissue, a nervous tissue, an epithelial tissue, a mineralized tissue, a meristematic tissue, a permanent tissue, a simple tissue, a parenchyma, a collenchyma, a sclerenchyma, an epidermis, a xylem and a phloem.
As used herein, the term “formulation” generally refers to, but not limited to, the process in which various kinds of chemical substances and active drugs are combined to produce a final medicinal product. The formulation type includes, but not limited to, a tablets or a capsules, a cream, an ointment, a gel, a paste, a powder, a spray and an injection.
As used herein, the term “metabolic disorder” generally refers to, but not limited to, a disorder which can happen when abnormal chemical reactions in the body alter the normal metabolic process. The metabolic disorder can also be defined as inherited single gene anomaly, most of which are autosomal recessive.
As used herein, the term “hematopoietic stem cell” generally refers to, but not limited to the stem cells that give rise to all the other blood cells through the process of haematopoiesis.
As used herein, the term “endothelial progenitor cells” generally refers to, but not limited to, a term that has been applied to multiple different cell types that play role in the regeneration of the endothelial lining of blood vessels.
As used herein, the term “adult stem cells” generally refers to, but not limited to an undifferentiated cells, found throughout the body after development, that multiply by cell division to replenish dying cells and regenerate damaged the tissues.
As used herein, the term “pluripotent stem cell” generally refers to but not limited to the embryonic stem cells which originate as inner mass cells within the blastocyst. The stem cells can become any tissue in the body, excluding a placenta.
9
As used herein, the term “cell counting” generally refers to but not limited to, any of various methods for the counting or similar quantification of cells in the life sciences, including medical diagnosis and treatment.
As used herein, the term “capsule (pharmacy)” generally refers to but not limited to an any range of dosage forms—techniques used to enclose medicines—in a relatively stable shell known as the capsule, allowing the capsule to, for example, be taken orally or be used as suppositories.
As used herein, the term “extract” generally refers to, but not limited to, a substance made by extracting a part of a raw material, often by using a solvent such as an ethanol or water. The extracts may be sold as tinctures or in powder form.
As used herein, the term "solanum trilobatum” generally refers to, but not limited to, an herb that can be consumed by mildly frying the solanum trilobatum in an oil or a ghee and then grinding the solanum trilobatum.
As used herein, the term "mimosa pudica" generally refers to, but not limited to, a creeping annual or perennial herb of the pea family fabaceae often grown for the mimosa pudica curiosity value, the compound leaves fold inward and droop when touched or shaken, defending the mimosa pudica from harm, and re-open a few minutes later.
As used herein, the term "tribulus terrestris” generally refers to, but not limited to, an annual plant in the caltrop family (zygophyllaceae) widely distributed around the world, that is adapted to grow in dry climate locations in which few other plants can survive.
As used herein, the term “wheat grass” generally refers to, but not limited to, a food prepared from the cotyledons of the common wheat plant, a triticum aestivum (subspecies of the family poaceae). The wheat grass is sold either as a juice or powder concentrate. The wheatgrass differs from wheat malt in that the wheatgrass is served freeze-dried or fresh, while the wheat malt is convectively dried.
10
As used herein, the term “mg” generally refers to, but not limited to, a unit of mass or weight equal to one thousandth of a gram, and equivalent to 0.0154 grain.
As used herein, the term “stem cells” generally refers to, but not limited to, undifferentiated biological cells that can differentiate into specialized cells and can divide through mitosis to produce more stem cells. The stem cells are of two types, the embryonic stem cell and the adult stem cell. The embryonic stem cells are derived from a four- or five-day-old human embryo that is in the blastocyst phase of development. The adult stem cells exist throughout the body after embryonic development and are found inside of different types of the tissues. The stem cells have been found in the tissues such as the brain, bone marrow, blood, blood vessels, skeletal muscles, skin, and the liver. The stem cells remain in a quiescent or non-dividing state for years until activated by disease or tissue injury.
As used herein, the term “debilities” generally refers to, but not limited to, a weakened or enfeebled state of the body.
As used herein, the term “diabetes” generally refers to, but not limited to, a group of metabolic diseases in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger.
As used herein, the term “arthritis” generally refers to, but not limited to, a form of joint disorder that involves the inflammation in one or more joints. The major complaint of individuals who have the arthritis is joint pain. Pain is often constant, and may be localized to the joint affected. The pain from the arthritis is due to the inflammation that occurs around the joint, damage to the joint from disease, daily wear and tear of joint, muscle strains caused by forceful movements against stiff painful joints and fatigue.
As used herein, the term “neurodegeneration” generally refers to, but not limited to, an umbrella term for the progressive loss of structure or function of a neurons, including death of the neurons. Many neurodegenerative diseases including an amyotrophic lateral sclerosis, a parkinson’s, an
11
alzheimer's, and a huntington's occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells.
As used herein, the term “transplantation” generally refers to, but not limited to, a transfer (engraftment) of human cells, the tissues or organs from a donor to a recipient with the aim of restoring functions in the body. When the transplantation is performed between different species, e.g. animal to human, the transplantation is named a xenotransplantation.
As used herein, the term “cerebral palsy” generally refers to, but not limited to, a group of permanent movement disorders that appear in early childhood. Signs and symptoms vary between people. Often, symptoms include poor coordination, stiff muscles, weak muscles, and tremors. There may be problems with sensation, vision, hearing, swallowing and speaking.
As used herein, the term “autism” generally refers to, but not limited to, a neurodevelopmental disorder characterized by impaired social interaction, verbal and non-verbal communication, and restricted and repetitive behavior. Parents usually notice signs in the first two years of their child's life. These signs often develop gradually, though some children with the autism reach their developmental milestones at a normal pace and then regress. The diagnostic criteria require that symptoms become apparent in early childhood, typically before age three.
As used herein, the term “antioxidant” generally refers to, but not limited to, a molecule that inhibits an oxidation of other molecules. The oxidation is a chemical reaction that can produce free radicals, leading to chain reactions that may damage cells. The antioxidants such as a thiols or an ascorbic acid (vitamin C) terminate these chain reactions.
As used herein, the term “ hepatoprotective properties” generally refers to, but not limited to, an ability to prevent damage to the liver.
As used herein, the term “antimicrobial” generally refers to, but not limited to, an agent that kills a microorganisms or inhibits the microorganisms growth. The antimicrobial medicines can be grouped according to the microorganisms the antimicrobial act primarily against. For
12
example, the antibacterial are used against a bacteria and an antifungal are used against a fungus. The antimicrobial can also be classified according to the antimicrobial function. Agents that kill microbes are called a microbicidal, while those that merely inhibit the microorganism growth are called a biostatic. The use of the antimicrobial medicines to treat infection is known as an antimicrobial chemotherapy.
As used herein, the term “analgesic” generally refers to, but not limited to, any member of the group of drugs used to achieve the analgesia, relief from pain.
As used herein, the term “anti-inflammatory” generally refers to, but not limited to, the property of a substance or treatment that reduces an inflammation or swelling. The anti-inflammatory drugs make up about half of the analgesics, remedying pain by reducing the inflammation as opposed to opioids, which affect the central nervous system.
As used herein, the term “antidiarrhoeal” generally refers to, but not limited to, any medication which provides symptomatic relief for diarrhoea.
As used herein, the term “antimalarial” generally refers to, but not limited to, medications designed to prevent or cure malaria.
As used herein, the term “cancer” generally refers to, but not limited to, a malignant tumor or a malignant neoplasm, is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Not all tumors are cancerous; a benign tumors do not spread to other parts of the body. Possible symptoms include: a new lump, abnormal bleeding, a prolonged cough, unexplained weight loss, and a change in bowel movements among others While these symptoms may indicate the cancer, the cancer may also occur due to other issues. There are over 100 different known cancers that affect humans.
As used herein, the term “blood” generally refers to, but not limited to, a bodily fluid in humans and other animals that delivers necessary substances such as nutrients and oxygen to the cells and transports metabolic waste products away from those same cells. When the blood
13
reaches the lungs, gas exchange occurs when carbon dioxide is diffused out of the blood into the pulmonary and oxygen is diffused into the blood. This oxygenated blood is pumped to the left hand side of the heart in the pulmonary vein and enters the left atrium. From here the blood passes through the mitral valve, through the ventricle and taken all around the body by the aorta. The blood contains antibodies, nutrients, oxygen and much more to help the body work.
As used herein, the term “anemia” generally refers to, but not limited to, decrease in the amount of the red blood cells (RBCs) or hemoglobin in the blood. The anemia can also be defined as a lowered ability of the blood to carry oxygen. When the anemia comes on slowly the symptoms are often vague and may include: feeling tired, weakness, shortness of breath or a poor ability to exercise.
As used herein, the term “high blood pressure” generally refers to, but not limited to, a common condition in which the long-term force of the blood against your artery walls is high enough that high blood pressure may eventually cause health problems, such as heart disease.
As used herein, the term “VSELs” generally refers to, but not limited to, a population of an epiblast-derived cells that are deposited during early gastrulation in developing the tissues/organs and play an important role in turnover of tissue specific/committed stem cells.
As used herein, the term “RBC” generally refers to, but not limited to most common type of blood cell and the vertebrate organism's principal means of delivering oxygen (O2) to the body tissues via blood flow through the circulatory system. The RBCs take up oxygen in the lungs or gills and release the VSELs into the tissues while squeezing through the body's capillaries.
As used herein, the term “pernicious anemia” generally refers to, but not limited to, a one of many types of the larger family of megaloblastic anemias. One way the pernicious anemia can develop is by loss of gastric parietal cells, which are responsible, in part, for the secretion of intrinsic factor, a protein essential for subsequent absorption of vitamin B12 in the ileum.
14
As used herein, the term “HSCs” generally refers to, but not limited to, the hematopoietic stem cells (HSCs) or a hemocytoblasts are the stem cells that give rise to all the other cells through the process of haematopoiesis. The HSCs are derived from mesoderm and located in the red bone marrow, which is contained in the core of most bones.
As used herein, the term “adult pluripotent stem cells” generally refers to, but not limited to, the stem cells which maintain and repair the tissue in which the adult pluripotent stem cells are found. The adult pluripotent stem cells can be found in children, as well as adults. The pluripotent adult stem cells are rare and generally small in number, but the adult pluripotent stem cells can be found in umbilical cord blood and other tissues. A bone marrow is a rich source of the adult stem cells, which have been used in treating several conditions including spinal cord injury, liver cirrhosis and end stage heart failure.
The present invention relates to a formulation and a method for a capsule and more particularly, the present invention relates to the formulation and method for a capsule to enhance the natural population of a stem cell in a body and to enhance regeneration and rejuvenation in a tissue.The capsule comprises a solanum trilobatum, a mimosa pudica, a tribulus terrestris and a wheat grass.
The applicant has already filed trademark application for the formulation of the capsule and named it StemedTM.
The concentration of the solanum trilobatum in the present invention formulation is selected from a range, but not limited to, 25mg-250mg. In the preferred embodiment of the present invention formulation the concentration of the solanum trilobatum is 125mg.
The concentration of the mimosa pudica in the present invention formulation is selected from a range, but not limited to, 10mg-250mg. In the preferred embodiment of the present invention formulation the concentration of the mimosa pudica is 125mg.
15
The concentration of the tribulus terrestris in the present invention formulation is selected from a range, but not limited to, 10mg-250mg. In the preferred embodiment of the present invention formulation the concentration of the tribulus terrestris is 125mg.
The concentration of the wheat grass in the present invention formulation is selected from a range, but not limited to, 20mg-250mg. In the preferred embodiment of the present invention formulation the concentration of the wheat grass is 125mg.
The concentration of the ingredients in the present invention formulation is selected from a range, but not limited to, 300mg-500mg. In the preferred embodiment of the present invention, the concentration of the ingredients in the present invention formulation is 500mg.
Another embodiment of the present invention provides a capsule formulation including 125mg solanum trilobatum, 125mg tribulus terrestris, 125mg mimosa pudica and 125mg wheat grass. The total range of concentration of ingredients used in the capsule is 500mg.
Example 1
Fig. 1 illustrates the tabular representation of measurement of number of a very small embryonic like stem cells(VSELs) per ml of blood in patients. The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness(control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated).
Fig. 2 illustrates a graphical representation of measurement of number of the very small embryonic like stem cells(VSELs) per ml of blood in patients which had been taken at a time period of 1st month, 2nd month, 3rd month and 4th month. Four formulation a capsule formulation variants were made and used in this experiment e.g. alpha(a), beta(ß), gamma(?), delta(d). The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness (control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated). The y axis represent the very small embryonic like stem cells(VSELs) per ml of blood and x axis represent the formulation or
16
capsule formulation variants. The experimental results displayed that using (ß) capsule formulation variant solution enhanced the (VSELs) in blood as compare to other capsule formulation variants.
Example 2
Fig. 3 illustrates a tabular representation of number of the red blood cells(RBCs) per ml of bloodx109 in patients. The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness(control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated)
Fig. 4 illustrates a graphical representation of number of the red blood cells(RBCs) per ml of bloodx109 in patients which had been recorded at a time period of 1st month, 2nd month, 3rd month and 4th month. Four formulation capsule formulation variants were made and used in this experiment e.g. alpha(a), beta(ß), gamma(?), delta(d). The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness(control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated). The experimental results displayed that using (ß) capsule formulation variant solution enhanced the (RBCs) per ml of bloodx109 compare to other capsule formulation variants.
Example 3
Fig. 5 illustrates a tabular representation of number of the hematopoietic stem cells(HSCs) per ml of blood in patients. The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness(control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated).
Fig. 6 illustrates a graphical representation of number of the hematopoietic stem cells(HSCs) per ml of blood in patients which had been recorded at a time period of 1st month, 2nd month, 3rd month and 4th month. Four formulation capsule formulation variants were made and used in this experiment e.g. alpha(a), beta(ß), gamma(?), delta(d). The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for
17
wellness(control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated). The experimental results displayed that using (ß) capsule formulation variant solution enhanced the hematopoietic stem cells(HSCs) per ml of blood compare to other capsule formulation variants. The y axis represents the hematopoietic stem cells(HSCs) per ml of blood and x axis represent the formulation or capsule formulation variants.
Example 4
Fig. 7 illustrates a tabular representation of number of the adult pluripotent stem cells per ml of blood in patients. The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness(control treated) and the third one includes patients with the pernicious anemia treated with the capsule(treated).
Fig. 8 illustrates a graphical representation of number of the adult pluripotent stem cells per ml of blood in patients which had been recorded at a time period of 1st month, 2nd month, 3rd month and 4th month. Four formulation/ capsule formulation variants were made and used in this experiment e.g. alpha(a), beta(ß), gamma(?), delta(d). The samples used are of three types, first one is not treated with the capsule(control) and second one treated with the capsule for wellness (control treated claims rather than by the foregoing description or drawings. Consequently, while the present invention has been described with reference to particular embodiments, modifications of structure, sequence, materials and the like apparent to those skilled in the art still fall within the scope of the invention as claimed by the applicant) and the third one includes patients with the pernicious anemia treated with the capsule(treated). The experimental results displayed that using (ß) capsule formulation variant solution enhanced the adult pluripotent stem cells per ml of blood compare to other capsule formulation variants. The y axis represents the adult pluripotent stem cells per ml of blood and x axis represent the formulation or capsule formulation variants.
Those skilled in the art to which the present invention pertains may make modifications resulting in other embodiments employing principles of the present invention without departing from its spirit or characteristics, particularly upon considering the foregoing teachings. Accordingly, the described embodiments are to be considered in all respects only as illustrative, and not restrictive, and the scope of the present invention is, therefore, indicated by the appended claims rather than by the foregoing description or drawings. Consequently, while the present invention
18
has been described with reference to particular embodiments, modifications of structure, sequence, materials and the like apparent to those skilled in the art still fall within the scope of the invention as claimed by the applicant. The present invention is capable of being industrially made. Hence the present invention also qualifies the Industrial applicability criteria ,CLAIMS:A capsule formulation for increasing the stem cells in body, the capsule formulation comprises:
a solanum trilobatum, the solanum trilobatum concentration in range of range of 25mg-250mg;
a mimosa pudica, the mimosa pudica concentration in range of 10mg-250mg;
a tribulus terrestri, the tribulus terrestri concentration in range of 10mg-250mg;
a wheat grass, the wheat grass concentration in range of 20mg-250mg.
wherein, the capsule concentration in range of 300mg-500mg and the capsule is a stemed capsule.
2 The formulation as claimed in claim 1, wherein the solanum trilobatum concentration is 125mg.
3 The formulation as claimed in claim 1, wherein the mimosa pudica concentration is 125mg.
4 The formulation as claimed in claim 1, wherein the tribulus terrestri concentration is 125mg.
5 The formulation as claimed in claim 1, wherein the wheat grass concentration is 125mg.
6 The formulation as claimed in claim 1, wherein the stemed capsule concentration is 500mg.
7 A capsule formulation for increasing the stem cell in body, the capsule formulation comprises:
a solanum trilobatum, the solanum trilobatum concentration is 125mg;
a mimosa pudica, the mimosa pudica concentration is 125mg;
a tribulus terrestri, the tribulus terrestri concentration is 125mg;
a wheat grass, the wheat grass concentration is 125mg.
wherein the capsule concentration is 500mg and the capsule is a stemed capsule.
20
8 A method for increasing the stem cell in body, the method comprises:
a capsule formulation, the capsule formulation having:
a solanum trilobatum, the solanum trilobatum concentration in range of range of 25mg-250mg;
a mimosa pudica, the mimosa pudica concentration in range of 10mg -250mg;
a tribulus terrestri, the tribulus terrestri concentration in range of 10mg-250mg;
a wheat grass, the wheat grass concentration in range of 20mg-250mg.
wherein the capsule concentration in range of 300mg-500mg and and the capsule is a stemed capsule.